274 related articles for article (PubMed ID: 25085026)
1. Side effects of targeted therapies: rash.
Eaby-Sandy B; Lynch K
Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
[TBL] [Abstract][Full Text] [Related]
2. Non-rash dermatologic adverse events related to targeted therapies.
Bryce J; Boers-Doets CB
Semin Oncol Nurs; 2014 Aug; 30(3):155-68. PubMed ID: 25085027
[TBL] [Abstract][Full Text] [Related]
3. Clinical approaches to minimize rash associated with EGFR inhibitors.
Oishi K
Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
[TBL] [Abstract][Full Text] [Related]
4. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
5. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
6. Cardiac side effects of targeted therapies.
Shank Coviello J
Semin Oncol Nurs; 2014 Aug; 30(3):175-82. PubMed ID: 25085029
[TBL] [Abstract][Full Text] [Related]
7. Optic and otic side effects of molecular targeted therapies.
O'Leary C
Semin Oncol Nurs; 2014 Aug; 30(3):169-74. PubMed ID: 25085028
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
9. Assessment and management of gastrointestinal toxicities and lab abnormalities related to targeted therapy.
Fischer-Cartlidge EA
Semin Oncol Nurs; 2014 Aug; 30(3):183-9. PubMed ID: 25085030
[TBL] [Abstract][Full Text] [Related]
10. Common side effects of anti-EGFR therapy: acneform rash.
Sipples R
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
[TBL] [Abstract][Full Text] [Related]
11. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
13. EGFR-targeted therapy and related skin toxicity.
Morse L; Calarese P
Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
[TBL] [Abstract][Full Text] [Related]
14. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
[TBL] [Abstract][Full Text] [Related]
15. [Managing cutaneous toxicities of targeted therapies].
Kiyohara Y
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1597-602. PubMed ID: 23152009
[TBL] [Abstract][Full Text] [Related]
16. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
17. Managing skin toxicities related to panitumumab.
Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
[TBL] [Abstract][Full Text] [Related]
18. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.
Lacouture ME
Cancer Nurs; 2007; 30(4 Suppl 1):S17-26. PubMed ID: 17666987
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
[TBL] [Abstract][Full Text] [Related]
20. [Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy].
Matzka M; Stöhr D; Colditz A; Köck-Hódi S; Koller M; Mayer H
Pflege; 2017 Jan; 30(1):9-17. PubMed ID: 27901405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
